Overview

MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent mild-to-moderate Japanese asthma patients to permit further clinical investigation
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.